Plasma therapy leads to an increase in functional IgA and IgM concentration in the blood and saliva of a patient with X-linked agammaglobulinemia by Langereis, J.D. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/204160
 
 
 
Please be advised that this information was generated on 2019-07-08 and may be subject to
change.
Langereis et al. J Transl Med          (2019) 17:174  
https://doi.org/10.1186/s12967-019-1928-x
RESEARCH
Plasma therapy leads to an increase 
in functional IgA and IgM concentration 
in the blood and saliva of a patient with X-linked 
agammaglobulinemia
Jeroen D. Langereis1,2* , Joannes F. M. Jacobs2,3, Marien I. de Jonge1,2 and Marcel van Deuren2,4
Abstract 
Background: Patients with X-linked agammaglobulinemia (XLA) are protected against invasive bacterial infections 
due to IgG replacement therapy, but are still at higher risk for mucosal infections of the gut and respiratory tract. This 
might be explained by to the lack of IgA and IgM, as these antibodies are especially important for protection against 
invading bacterial pathogens on the mucosal surface.
Methods: In an attempt to eliminate a chronic norovirus infection in a patient with X-linked agammaglobulinemia, 
fresh frozen plasma (FFP) was given two times a week for 3 weeks. At each visit, pre- and post-FFP infusion serum and 
saliva was collected to determine IgG-, IgA- and IgM-concentrations and serum half-life was calculated. Functionality 
of the immunoglobulins pre- and post-FFP infusion in both serum and saliva was tested by measuring complement 
activation, agglutination and killing of non-typeable Haemophilus influenzae (NTHi).
Results: Administration of FFP failed to eradicate the chronic norovirus infection. Serum IgA and IgM half-life was 
4.2 ± 0.3 and 3.8 ± 0.3 days, respectively. The presence of serum IgM was associated with increased complement 
binding and complement-mediated killing of NTHi. IgA in saliva was detectable post-FFP and was associated with 
increased agglutination of NTHi. IgM in saliva was not detectable.
Conclusions: We conclude that FFP treatment, although ineffective in clearing a chronic norovirus infection in 
this single patient, might be beneficial to prevent or eliminate bacterial infections in XLA patients by increasing 
IgM dependent complement-mediated killing in serum and IgA dependent bacterial agglutination on the mucosal 
surface.
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Background
Immunoglobulins are essential for defense against invad-
ing bacterial pathogens, as is clearly illustrated by the 
high infectious burden in patients with agammaglobu-
linemia such as X-linked agammaglobulinemia (XLA) [1], 
which is caused by mutations in Bruton’s Tyrosine Kinase 
(Btk) resulting in the failure of B-lymphocyte maturation 
[2]. The protective effect of immunoglobulins is based 
on three principle actions: neutralization/agglutination, 
opsonization and complement activation [3]. The protec-
tive activity of IgM is mainly found in the blood, of IgG in 
the blood and extravascular sites and of IgA at mucosal 
surfaces [3].
Treatment of patients with XLA patients mainly 
relies on IgG replacement therapy (IgGRT), which is 
effective in preventing invasive bacterial infections, and 
increases patient survival considerably [4]. However, a 
large proportion of patients with agammaglobulinemia 
still experience recurrent upper and lower respiratory 
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tract infections [4–6]. Pneumonia in XLA patients 
is mainly caused by H. influenzae (58%), followed by 
Streptococcus pneumoniae (17%) and Staphylococcus 
aureus (17%). Chronic sinusitis is also mainly caused by 
H. influenzae (67%), followed by S. pneumoniae (14%) 
and S. aureus (10%) [7]. In contrast, H. influenzae infec-
tions are rarely seen in invasive infections such as sep-
sis, which is mainly caused by Pseudomonas aeruginosa 
and S. pneumoniae [4].
It appears that the persistent lack of IgA and IgM 
strongly contributes to reduced protection against 
invading mucosal bacterial pathogens due to deficient 
IgA-dependent agglutination at the mucosal surface 
and impaired IgM-dependent early complement acti-
vation after invasion. This is supported by examining 
patient cohorts with selective IgA and IgM deficiency, 
who have an increased risk for recurrent respiratory 
tract infections as well [8, 9].
Current IgGRT preparations contain IgG but are 
devoid of IgA and IgM [10]. There are a few prepara-
tions that also contain IgA and IgM antibodies, but 
none of them are used in clinical practice for the treat-
ment of agammaglobulinemia to date [10]. In the early 
1970s, fresh frozen plasma (FFP) was given to agamma-
globulinemia patients. FFP infusions are well tolerated 
and increased serum IgG, IgA and IgM levels, however, 
frequent infusions are required to maintain acceptable 
serum antibody concentrations [11, 12].
Norovirus infection is the most frequent enteric 
pathogen found in patients with inherited immune 
deficiencies, including 2 out of 5 patients with agam-
maglobulinemia [13]. Treatments including increasing 
IVIG trough levels, enteral administration of immu-
noglobulins and breast milk as source of secretory IgA 
had limited effects in norovirus eradication [14, 15]. In 
recent years, we saw 5 agammaglobulinemia patients 
with normal supplemented IgG concentrations, but still 
lacking IgA and IgM, with a chronic norovirus infec-
tion. Because IgA deficiency is rather common and 
not associated with norovirus infection, we hypoth-
esized that IgM might be involved in defense against 
norovirus because norovirus-specific IgM is detected in 
healthy individuals [16]. Therefore, we decided to eval-
uate the effect of 2 units (250–295 mL) FFP containing 
IgA and IgM two times a week for 3 weeks in a 22-years 
old XLA patient with, besides recurrent respiratory 
tract infections caused by Haemophilus influenzae, a 
chronic norovirus infection. During this therapy, we 
had the opportunity to collect serum and saliva pre-and 
post-FFP infusion. Serum samples were used to calcu-
late IgA and IgM-serum half-life as well as to measure 
the contribution serum IgM to complement-mediated 
killing of non-typeable H. influenzae (NTHi). Saliva 
samples were used to determine the contribution of 
saliva IgA to bacterial agglutination.
Methods
Ethics statement
The collection of saliva was approved by the ethics com-
mittee of the Radboudumc, Nijmegen, the Netherlands 
(#2018-4044). Collection of blood/serum was performed 
for routine clinical diagnostics. All experiments were car-
ried out in accordance with local guidelines and regula-
tions and complies with the Declaration of Helsinki and 
the Good Clinical Practice guidelines.
Serum preparation and storage
Blood was drawn in vacutainer gel serum tubes (BD Bio-
sciences) and serum was prepared by centrifuging blood 
for 10  min at 4000×g and serum aliquots were stored 
at − 20  °C. Serum was thawed directly prior to use and 
diluted in Hank’s balanced salt solution (HBSS), with-
out phenol red, containing  Ca2+ and  Mg2+ + 0.1% gela-
tin (HBSS3+). For complement-inactivation, serum was 
heat-inactivated (HI) by incubation for 20 min at 56 °C.
Saliva preparation and storage
Unstimulated saliva was collected by spitting for 15 min 
in a 50 mL Falcon tube and kept on ice. Saliva was trans-
ferred to a 1.5 mL Eppendorf tube and particles were pel-
leted by centrifuging 10 min at 16,100×g. Saliva aliquots 
were stored at − 80 °C.
Bacterial growth conditions and storage
NTHi strain 3655 [17] was grown in a shaker incuba-
tor at 37  °C in brain heart infusion (BHI) broth (Bec-
ton–Dickinson) supplemented with 10  μg/mL haemin 
(Sigma-Aldrich) and 2  μg/mL β-nicotinamide adenine 
dinucleotide (Merck) (sBHI) to an optical density at 
620 nm = 0.5 and aliquots with 16% glycerol were stored 
at − 80 °C.
IgG, IgM and IgA measurements
Serum IgG, IgM and IgA concentrations were deter-
mined by the central diagnostic laboratory of the Rad-
boudumc on a Cobas 6000 analyzer (Roche, Basel, 
Switzerland) according to manufacturer’s guidelines. 
Serum IgA and IgM half-life was calculated using the fol-
lowing formula: number of days between FFP infusion/
(log0.5 (Ig level pre/Ig level post)). Half-life was calculated 
from 2nd to 3rd, 3rd to 4th, 4th to 5th and 5th to 6th FFP 
infusion.
Saliva IgG, IgM and IgA concentrations were deter-
mined by enzyme-linked immunosorbent assay (ELISA) 
following manufacturer’s protocol (Thermo Fisher). For 
IgG, saliva was diluted 20- and 50-fold in assay buffer 
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A. For IgA, patient saliva was diluted 10- and 20-fold in 
assay buffer A and control saliva was diluted 2000- and 
5000-fold in assay buffer A. For IgM, saliva was tenfold 
diluted in assay buffer A.
Flow cytometry
NTHi strain 3655 stock was thawed and 25 μL bacteria 
were added per well of a V-bottom plate and pelleted by 
centrifuging with 3200×g for 5  min. Supernatant was 
removed by decanting the plate and bacteria were sus-
pended into 50 μL PBS and pelleted by centrifuging with 
3200×g for 5 min. Supernatant was removed by decant-
ing the plate and bacteria were suspended into 50 µL 10% 
HI serum supplemented with 5% agammaglobulinemia 
as complement source diluted in HBSS3+ for comple-
ment binding experiments, 10% HI serum or 10% HI 
pooled normal human serum (NHS) diluted in HBSS3+ 
for antibody binding experiments or undiluted saliva 
and incubated 30 min at 37 °C. Bacteria were pelleted by 
centrifuging with 3200×g for 5 min and supernatant was 
removed by decanting. Bacteria were fixed in 100 µL 2% 
paraformaldehyde in PBS for 20 min in at room tempera-
ture. Bacteria were pelleted by centrifuging with 3200×g 
for 5 min and supernatant was removed by decanting. All 
antibody incubations were performed for 15 min at room 
temperature in 50  µL PBS + 2% bovine serum albumin 
(BSA). Surface-bound complement C3 and complement 
complex C5b9 were detected with 1:500-diluted FITC-
labelled polyclonal goat anti-human C3 (MP biomedi-
cals) and 1:100-diluted monoclonal mouse anti-human 
C5b9 (Clone aE11, Santa Cruz Biotechnology) followed 
by 1:200-diluted PE-labelled goat anti-mouse IgG (H + L) 
(Thermo Fisher), respectively. Surface bound IgG, IgM or 
IgA was detected with 1:500-diluted Fcγ fragment-spe-
cific PE-labelled AffiniPure goat anti-human IgG (Jackson 
ImmunoResearch), 1:500-diluted Fc5μ fragment-specific 
Alexa  Fluor® 647 AffiniPure goat anti-human IgM (Jack-
son ImmunoResearch) or 1:100-diluted α-chain-specific 
FITC-labelled polyclonal goat anti-human IgA (Sigma-
Aldrich), respectively. Surface binding of C3, C5b9, IgG, 
IgM and IgA was determined by flow cytometry using a 
FACS LSR II instrument (BD Biosciences) and expressed 
in mean fluorescence intensity (MFI) in arbitrary units 
(AU). Data were analysed by using FlowJo version 10.4.1. 
The percentage agglutination was determined by flow 
cytometry in the saliva-incubated bacterial samples as 
previously described [18].
Bacterial survival assays
NTHi strain 3655 stock was thawed, pelleted by cen-
trifugation with 16,100×g for 2  min. Supernatant was 
removed and bacteria were suspended into 1  mL PBS 
and pelleted by centrifugation with 16,100×g for 2 min. 
Bacteria were suspended into PBS and diluted to an 
 OD620 = 0.1 in PBS and diluted 10,000-fold in HBSS3 + to 
obtain a concentration of ~ 200,000  CFU/mL. Fifty µL 
bacteria were mixed with 25  μL 40% HI patient serum 
day 0 pre or day 0 post and 25 μL 20% agammaglobuline-
mia patient serum or 25 μL 40% HI patient serum day 0 
pre or day 0 post and 25  μL 20% HI agammaglobuline-
mia patient serum diluted in HBSS3+ and incubated 
1 h at 37 °C. Samples were diluted 10- and 100-fold with 
PBS and three droplets of 20 μL of the undiluted, 10 and 
100-fold diluted bacteria were plated on sBHI plates 
and grown overnight at 37 °C and 5%  CO2. Survival was 
determined by dividing the colony forming unit (CFU) 
counts in 10% NHS by the CFU count in HI-NHS after 
1-h incubation. Survival of all NTHi strains was deter-
mined in three independent experiments and the average 
of the three experiments was depicted in the results.
Statistical analysis
Statistical analyses were performed with GraphPad Prism 
version 5.03 for Windows (GraphPad Software, Inc.). 
Differences were considered significant at P < 0.05. The 
specific statistical tests that were used for the various 
experiments are specified in the manuscript text or figure 
legends. The data is presented as mean values ± standard 
error of the mean, range indicate minimum and maxi-
mum values.
Results
Patient characteristics
The patient, now 22 years old, was diagnosed with XLA 
at age of 2 years. From that age he was treated with intra-
venous IgGRT, currently every 2 weeks (660 mg/kg) and 
vitamin B12 supplements. Since childhood, he experi-
enced frequent respiratory infections, mainly caused by 
H. influenza requiring courses of antibiotics. Bronchiec-
tasis was diagnosed at age 11 years. Next to respiratory 
infections, the patient experienced gastrointestinal infec-
tions with Giardia lamblia and Clostridium difficile. At 
the age of 17 years old, he presented with weight loss and 
diarrhea and stools were found positive for norovirus. 
The weight loss stabilized but stool samples remained 
positive for norovirus.
This patient was given FFP two times a week for 
3 weeks as treatment to eliminate the chronic norovirus 
infection. However, administration of FFP did not result 
in the eradication of the norovirus as determined by a 
positive norovirus stool samples during and 1 week after 
treatment.
Half‑life of unmodified serum IgA and IgM in a XLA patient
Both serum IgA and IgM levels were undetectable prior 
to FFP infusion at day 0 (detection limit 0.04 g/L). After 
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the first FFP infusion, serum IgA and IgM concentration 
increased to 0.22 and 0.08  g/L, respectively (Fig.  1b, c). 
At the next visit on day 3, serum IgA was decreased to 
0.10  g/L, whereas serum IgM was below the detection 
limit of 0.04  g/L. At subsequent visits, serum IgA and 
IgM levels remained above the detection limit and slowly 
increased to 0.58 and 0.14  g/L after the last (6th) FFP 
infusion, respectively. Of note, these concentrations are 
still below the lower limit of normal serum IgA (0.7 g/L) 
and IgM (0.4 g/L) observed in healthy individuals [19].
Serum IgA and IgM half-life was calculated from 
the immunoglobulin levels post- and pre-FFP infusion 
as shown in Fig.  1. Half-life of IgA in this patient was 
4.2 ± 0.3 days and IgM half-life was 3.8 ± 0.3 days.
Serum IgM increases complement C3 and C5b9 binding 
and complement‑mediated killing of non‑typeable 
Haemophilus influenzae
Binding of IgG in patient’s serum to the bacteria was rela-
tively stable and similar to that of pooled NHS (Fig. 2a). 
As expected, there was no binding of IgM to the bacte-
ria when serum was used that was collected at baseline 
(prior to 1st FFP infusion). Samples taken after FFP infu-
sions showed increased IgM binding to NTHi, although 
Fig. 1 FFP treatment increases serum IgA and IgM levels. Serum IgG (a), IgA (b) and IgM (c) levels were determined in pre- and post-FFP treatment 
serum. The arrow indicates IgGRT that was given once together with the FFP treatment
Fig. 2 Serum IgM increases complement binding and bacterial killing. NTHi strain 3655 was incubated with 10% heat inactivated patient’s serum 
for 30 min and binding of IgG (a) and IgM (b) was determined by flow cytometry. Measurement of geometric mean fluorescence intensity (MFI) 
was depicted in arbitrary units (AU) (n = 4, mean ± standard error of the mean). The arrow indicates IgGRT that was given together with the FFP 
treatment. NTHi strain 3655 was incubated with 10% HI patient’s serum and 5% agammaglobulinemia patient’s serum as complement source for 
30 min and binding of complement C3 (c) and complement complex C5b9 (d) were determined by flow cytometry. Measurement of geometric 
mean fluorescence intensity (MFI) was depicted in arbitrary units (AU) (n = 4, mean ± standard error of the mean). Correlation between binding 
of C3 and IgG (e) or IgM (f) was determined by linear regression. Correlation between binding of C5b9 and IgG (g) or IgM (h) was determined 
by linear regression. Bacterial survival in 10% HI day 0 pre- and post-FFP serum supplemented with 5% agammaglobulinemia patient’s serum as 
complement source was determined (n = 5). Bacterial survival is depicted in percentage compared to 5% HI agammaglobulinemia patient’s serum 
as complement source (n = 5, mean ± standard error of the mean). A two-tailed paired t test was used for statistical analysis. *P < 0.05 (i)
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less than observed when pooled NHS was used, which 
can be explained by the lower IgM concentration, 
0.14  g/L in patient’s serum compared to 0.4–2.3  g/L as 
reference for normal serum IgM concentration [19].
Because both serum IgG and IgM can activate the clas-
sical pathway of complement activation, we determined 
complement C3 and complement complex C5b9 bind-
ing to the bacterial surface after incubation with patient’s 
serum. C3 and C5b9 binding increased after the 1st FFP 
infusions and then seemed to reach a plateau (Fig. 2c, d). 
Binding of C3 to the bacterial surface correlated signifi-
cantly with both IgG  (r2 = 0.3932, P = 0.0291) and IgM 
binding  (r2 = 0.4994, P = 0.0102) (Fig.  2e, f ), whereas 
C5b9 binding significantly correlated with binding of 
IgM  (r2 = 0.3932, P = 0.0291) (Fig.  2g, h). Therefore, the 
increase in serum IgM after FFP infusion appeared to 
increase complement binding to the bacterial surface. In 
order to relate this to a functional effect, we determined 
bacterial killing with day 0 pre-and post-FFP infusion 
serum and observed significantly more killing in post- 
(85 ± 6%) compared to pre-FFP infusion serum (74 ± 8%).
IgA in saliva increases agglutination of non‑typeable 
Haemophilus influenzae
Saliva IgG in patient’s samples was variable from 
0.3 to 4.5  mg/L. In three healthy controls this was 
0.46 ± 0.32  mg/L (range 0.13–1.1) (Fig.  3a). Post FFP 
patient’s saliva IgA ranged from 0.02 to 0.08  mg/L, 
far lower than 152 ± 49  mg/L (range 53–206) in 
healthy controls and reference values (120–200  mg/L) 
[19] (Fig.  3b). Saliva IgM was not measurable in 
patient’s samples. In three healthy controls this was 
3.91 ± 0.83 mg/L (2.39–5.25).
Saliva IgG and IgA bound to the bacterial surface 
was detectable (Fig. 3c, d). IgG levels in saliva did not 
correlate with binding of IgG to the bacterial surface 
 (r2 = 0.1324, P = 0.2450) (Fig.  3e). However, saliva IgA 
levels did significantly correlate with binding of IgA to 
the bacterial surface  (r2 = 0.8120, P < 0.0001) (Fig. 3f ).
One of the functions of IgA is to agglutinate bacte-
rial pathogens present on the mucosal surface [20]. 
Therefore, we determined bacterial agglutination with 
patient saliva by a flow cytometric-based assay devel-
oped in our lab [18]. Saliva samples collected before 
FFP infusion showed agglutination of 38% of the bacte-
ria (Fig.  3g). Subsequent saliva samples showed differ-
ences in agglutination ranging from 20 to 44%. Saliva 
IgG binding to the bacterial surface did not correlate 
with bacterial agglutination  (r2 = 0.0314, P = 0.5811) 
(Fig. 3h), but binding of saliva IgA to the bacterial sur-
face correlated significantly with bacterial agglutination 
 (r2 = 0.6141, P = 0.0026) (Fig. 3i).
Fig. 3 Saliva IgA increases bacterial agglutination. Saliva IgG (a) and IgA (b) was determined by ELISA (n = 4, mean ± standard error of the mean). 
The arrow indicates IgGRT that was given together with the FFP treatment. NTHi strain 3655 was incubated with patient saliva for 30 min and 
binding of IgG (c) and IgA (d) were determined by flow cytometry. Measurement of geometric mean fluorescence intensity (MFI) was depicted 
in arbitrary units (AU) (n = 5, mean ± standard error of the mean). Correlation between binding of saliva IgG (e) or IgA (f) to the bacterial surface 
and saliva IgG or IgA levels was determined by linear regression, respectively. Bacterial agglutination (g) was measured by flow cytometry (n = 5, 
mean ± standard error of the mean). Correlation between binding of saliva IgG (h) and IgA (i) to the bacterial surface and percentage agglutination 
was determined by linear regression
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Discussion
Half-life of serum immunoglobulins have been deter-
mined frequently in the 1960s by using radio-active 
labelled purified serum IgM [21–24]. At first, half-life 
of ~ 3  days was found [22–24], but later studies using 
improved isolation techniques not affecting IgM func-
tionality found a serum IgM half-life of ~ 5  days (range 
3.8–6.5  days) for healthy individuals [21]. Serum IgM 
half-life was also determined for patients with different 
diseases, including agammaglobulinemia and protein los-
ing enteropathy [21]. For 4 patients with agammaglobu-
linemia, serum IgM half-life was 4.2 days (range 2.2–6.5) 
[21], which is close to the 3.8 days found in this current 
study with a patient with XLA. IgM half-life was even 
lower for 4 patients with protein losing enteropathy, i.e. 
1.4  days (range 1.0–1.7) [21]. Although not confirmed, 
our patient might have some degree of protein losing 
enteropathy because he required a high IgGRT dose 
(330  mg/kg/week), which might explain the lower half-
life of IgA and IgM, as compared to the previous study in 
agammaglobulinemia [16].
FFP treatment increased serum IgA to 0.58  g/L and 
IgM to 0.14  g/L. As previously reported, FFP treatment 
used to eradicate chronic Campylobacter jejuni infec-
tions, increased serum IgA to detectable levels in two 
patients (0.42–0.56 g/L), which is in accordance to serum 
levels measured in our patient. In these two patients, IgM 
was only detectable in a single patient (0.48 g/L) [25]. In 
an earlier study, we showed that in vitro IgM supplemen-
tation increased complement binding and complement-
mediated killing of Campylobacter jejuni with serum 
from an agammaglobulinemia patient who suffered from 
a C. jejuni spondylodiscitis [26]. In vitro supplementation 
of serum from an agammaglobulinemia patient with IgM 
also increased complement-mediated killing of NTHi 
[27]. In the present study, we show that supplementation 
of IgM in  vivo by FFP treatment increases complement 
binding and complement-mediated killing of NTHi, 
which supports a role for serum IgM in complement-
mediated killing of bacterial pathogens even in the pres-
ence of normal levels of serum IgG.
A proportion of XLA patients experience recurrent 
upper and lower respiratory tract infections, from which 
a large part are caused by H. influenzae [4–7]. This is 
likely due to the absence of IgA and IgM at the mucosal 
surface. Serum IgA and IgM can be transported to the 
mucosal surface through the polymeric Ig receptor [28], 
therefore, we assessed the saliva concentrations of these 
immunoglobulin classes in this patient.
Although IgG serum concentrations were hardly 
influenced by FFP infusion, saliva IgG differed largely, 
underscoring the difficulties in acquiring reproducible 
saliva samples. We collected saliva in a tube using an 
unstimulated saliva collection method for 15  min. The 
amount of saliva varied between 0.5 and 3  mL, which 
might have contributed to differences in composition 
between samples, and thus IgG concentrations. Although 
patient saliva IgG concentrations varied between sam-
ples, levels were within or above the range of 3 healthy 
controls. Binding of saliva IgG to the surface of NTHi 
was constant and did not correlate with total saliva IgG 
concentrations, suggesting maximal IgG binding is 
already achieved at all saliva IgG concentrations.
Saliva IgA was undetectable at the time of the first 
two FFP infusions, but became detectable at all other 
time points, albeit with very low concentration. Patient 
saliva IgA levels were almost 2000-fold lower than nor-
mal saliva IgA levels, whereas patient’s serum IgA was 
only fourfold lower compared to normal serum IgA lev-
els, suggesting that most saliva IgA in healthy individu-
als is not transported from blood but produced locally. 
Our data is consistent with a study conducted more than 
50  years ago [29]. In this study, 5 agammaglobulinemia 
patients received between 1000 and 2000  mL plasma 
over a period of 1 to 3 days, which led to an increase in 
serum IgA to 1500 mg/L and saliva IgA levels to 1 mg/L 
in one of these patient, much lower compared to saliva of 
healthy individuals (120–200 mg/L) [19].
Although saliva IgA levels were very low, we showed 
a strong correlation between saliva IgA binding to the 
bacterial surface and bacterial agglutination. Bacterial 
agglutination by IgA was first acknowledged by using 
gastrointestinal secretions and colostrum [30]. Recently, 
secretory IgA and secretory IgM were found to bind and 
agglutinate Salmonella enterica serovar Typhimurium, 
thereby limiting infection and systemic dissemination 
in mice [31]. Whether the IgA levels in saliva, or other 
mucosal surfaces such as the gut, after FFP treatment, are 
sufficient to prevent or treat bacterial infections is not 
known.
The levels of IgA and IgM were at least not sufficient 
to resolve the chronic norovirus infection in the gas-
trointestinal tract of this patient. Kempf and cowork-
ers have tried various treatments to eradicate a chronic 
norovirus infection in a XLA patient, including nasogas-
trically administered pentaglobin containing IgM, how-
ever, without clinical response and persistent detection 
of norovirus by PCR [14]. Although it is thought that 
antibodies play a role in the clearance of norovirus infec-
tions [32], treatment with increasing IVIG trough levels, 
enteral administration of immunoglobulins and breast 
milk as source of secretory IgA had limited effects [14, 
15]. We have not determined the presence of norovi-
rus-specific antibodies in FFP, therefore, the failure for 
immunoglobulin preparations such as FFP in eradicating 
chronic norovirus infections might be due to the absence 
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of norovirus-specific antibodies, which should be deter-
mined in future studies.
An disadvantage of FFP infusions is the frequency of 
administration, at least twice a week, therefore, using FFP 
infusions is not suitable as maintenance therapy because 
of the high burden for the patient. However, the use of 
FFP, in combination with antibiotics, might contribute 
in clearing chronic or severe respiratory infections when 
administered for a limited timeframe.
A clear limitation of this study is the use of a single 
patient with XLA. Therefore, we cannot firmly conclude 
that FFP infusion is not effective in treating chronic 
norovirus infection in patients with XLA. However, by 
collecting serum and saliva at multiple timepoints from 
this single patient, we were able to follow the effects of 
FFP infusion on IgA and IgM serum and saliva levels, as 
well as the functional effect of these IgA and IgM level 
changes. FFP infusions in this currently used treatment 
regimen did result in detectable serum IgM concentra-
tions, but unfortunately not in saliva. This lack of IgM 
might explain the lack of effect on the norovirus infec-
tion. Clearly, more research using more patients is 
needed to identify strategies for the treatment of chronic 
norovirus infection in agammaglobulinemia patients.
Conclusions
In conclusion, the use of serum and saliva from an XLA 
patient receiving IgG supplementation every 2 weeks and 
FFP two times a week for 3 weeks has taught us that (1) 
low albeit detectable serum IgA and IgM levels can be 
reached by frequent FFP infusions, (2) serum half-life of 
IgA and IgM is 4.2 and 3.8 days, respectively, (3) a small 
increase in serum IgM increases complement-mediated 
killing of NTHi, (4) FFP induces detectable concentra-
tions of saliva IgA, which is associated with agglutination 
of NTHi, (5) FFP treatment in the current regimen did 
not result in detectable saliva IgM concentrations.
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